Newer, exciting drug screens for small molecule compounds that modulate DOCK3 conformational changes affecting DOCK3 and ELMO1 interactions have recently been published and could be explored for treating axonal injury and neurodegenerative diseases [36,54]. This evidence concerns the gene DOCK3 and neurodegenerative disease.